Urgent need for a new staging system in advanced colorectal cancer

Journal of Clinical Oncology

Volumn 26, Issue 29, 2008, Pages 4828-4833

  Poston, Graeme J ^a   Figueras, Joan ^b   Giuliante, Felice ^b   Nuzzo, Gennaro ^b   Sobrero, Alberto F ^b   Gigot, Jean Francois ^b   Nordlinger, Bernard ^b   Adam, Rene ^b   Gruenberger, Thomas ^b   Choti, Michael A ^b   Bilchik, Anton J ^b   Van Cutsem, Eric J D ^b   Chiang, Jy Ming ^b   D'Angelica, Michael I ^b  

^a UNIVERSITY HOSPITAL AINTREE   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

ADVANCED CANCER; CANCER ADJUVANT THERAPY; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; HUMAN; INOPERABLE CANCER; LIFE EXPECTANCY; LIVER METASTASIS; LIVER RESECTION; LONG TERM CARE; LYMPH NODE METASTASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PATIENT MONITORING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SURVIVAL RATE; SURVIVAL TIME;

COLORECTAL NEOPLASMS; HUMANS; LIVER NEOPLASMS; NEOPLASM STAGING; SURVIVAL ANALYSIS;

EID: 54349099052     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.17.6453     Document Type: Review

References (72)

1. Poston GJ: Standing on the shoulders of giants. Eur J Surg Oncol 34:253-255, 2008
2. Dukes CE: The surgical pathology of rectal cancer. J Clin Pathol 2:95-98, 1949
3. Astler VB, Coller FA: The prognostic significance of direct extension of carcinoma of the colon and rectum. Ann Surg 139:846-852, 1954
4. Resection of the liver for colorectal carcinoma metastases: A multi-institutional study of indications for resection: Registry of Hepatic Metastases. Surgery 103:278-288, 1988
5. Scheele J, Stang R, Altendorf-Hofmann A, et al: Resection of colorectal liver metastases. World J Surg 19:59-71, 1995
6. Nordlinger B, Van Cutsem E, Rougier P, et al: Does chemotherapy prior to liver resection increase the potential for cure in patients with metastatic colorectal cancer? A report from the European Colorectal Metastases Treatment Group. Eur J Cancer 43:2037-2045, 2007
7. Van Cutsem E, Nordlinger B, Adam R, et al: Towards a pan-European consensus on the treatment of patients with colorectal liver metastases. Eur J Cancer 42:2212-2221, 2006
8. Poston GJ, Adam R, Alberts S, et al: Onco-Surge: A strategy for improving resectability with curative intent in metastatic colorectal cancer. J Clin Oncol 23:7125-7134, 2005
9. Nordlinger B, Guiguet M, Vaillant JC, et al: Surgical resection of colorectal carcinoma metastases to the liver: A prognostic scoring system to improve case selection, based on 1568 patients. Association Francaise de Chirurgie Cancer 77:1254-1262, 1996
10. Figueras J, Burdio F, Ramos E, et al: Effect of subcentimeter nonpositive resection margin on hepatic recurrence in patients undergoing hepatectomy for colorectal liver metastases: Evidences from 663 liver resections. Ann Oncol 18:1190-1195, 2007
11. Figueras J, Ramos E, Lopez-Ben S, et al: Surgical treatment of liver metastases from colorectal carcinoma in elderly patients. When is it worthwhile? Clin Transl Oncol 9:392-400, 2007
12. Figueras J, Torras J, Valls C, et al: Surgical resection of colorectal liver metastases in patients with expanded indications: A single-center experience with 501 patients. Dis Colon Rectum 50:478-488, 2007
13. Fong Y, Fortner J, Sun RL, et al: Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: Analysis of 1001 consecutive cases. Ann Surg 230:309-318, 1999
14. Choti MA, Sitzmann JV, Tiburi MF, et al: Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg 235: 759-766, 2002
15. Tomlinson JS, Jarnagin WR, DeMatteo RP, et al: Actual 10-year survival after resection of colorectal liver metastases defines cure. J Clin Oncol 25: 4575-4580, 2007
16. Abdalla EK, Vauthey JN, Ellis LM, et al: Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ ablation for colorectal liver metastases. Ann Surg 239:818-825, 2004
17. Poston GJ: Radiofrequency ablation of colorectal liver metastases: Where are we really going? J Clin Oncol 23:1342-1344, 2005
18. Higgins H, Berger DL: RFA for liver tumors: Does it really work? Oncologist 11:801-808, 2006
19. Kanemitsu Y, Kato T, Hirai T, et al: Preoperative probability model for predicting overall survival after resection of pulmonary metastases from colorectal cancer. Br J Surg 91:112-120, 2004
20. Elias D, Sideris L, Pocard M, et al: Results of R0 resection for colorectal liver metastases associated with extrahepatic disease. Ann Surg Oncol 11:274-280, 2004
21. Bismuth H, Adam R, Levi F, et al: Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg 224: 509-520, 1996
22. Elias D, Liberale G, Vernerey D, et al: Hepatic and extrahepatic colorectal metastases: When resectable, their localization does not matter, but their total number has a prognostic effect. Ann Surg Oncol 12:900-909, 2005
23. Tournigand C, Andre T, Achille E, et al: FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study. J Clin Oncol 22:229-237, 2004
24. Goldberg RM, Sargent DJ, Morant RS, et al: A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22:23-30, 2004
25. Grothey A, Sargent D, Goldberg RM, et al: Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 22:1209-1214, 2004
26. Cals L, Rixe O, Francois E, et al: Dose-finding study of weekly 24-h continuous infusion of 5-fluorouracil associated with alternating oxaliplatin or irinotecan in advanced colorectal cancer patients. Ann Oncol 15:1018-1024, 2004
27. Tabernero J, Van Cutsem E, Diaz-Rubio E, et al: Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 25:5225-5232, 2007
28. Folprecht G, Lutz MP, Schoffski P, et al: Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma. Ann Oncol 17:450-456, 2006
29. Hurwitz H, Fehrenbacher L, Novotny W, et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-2342, 2004
30. Cunningham D, Humblet Y, Siena S, et al: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351:337-345, 2004
31. Saltz LB, Meropol NJ, Loehrer PJ Sr, et al: Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 22:1201-1208, 2004
32. Adam R, Aloia T, Levi F, et al: Hepatic resection after rescue with cetuximab treatment for colorectal liver metastases previously refractory to conventional systemic therapy. J Clin Oncol 25: 4593-4602, 2007
33. Abad A, Massuti B, Anton A, et al: Colorectal cancer metastasis resectability after treatment with the combination of oxaliplatin, irinotecan and 5-fluorouracil: Final results of a phase II study. Acta Oncol 1-7, 2007
34. Adam R, Avisar E, Ariche A, et al: Five-year survival following hepatic resection after neoadjuvant therapy for non-resectable colorectal [liver] metastases. Ann Surg Oncol 8:347-353, 2001
35. Adam R, Delvart V, Pascal G, et al: Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: A model to predict long-term survival. Ann Surg 240:644-657, 2004
36. Akasu T, Moriya Y, Takayama T: A pilot study of multimodality therapy for initially unresectable liver metastases from colorectal carcinoma: Hepatic resection after hepatic arterial infusion chemotherapy and portal embolization. Jpn J Clin Oncol 27:331-335, 1997
37. Alberts SR, Horvath WL, Sternfeld WC, et al: Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: A North Central Cancer Treatment Group phase II study. J Clin Oncol 23:9243-9249, 2005
38. Barone C, Nuzzo G, Cassano A, et al: Final analysis of colorectal cancer patients treated with irinotecan and 5-fluorouracil plus folinic acid neoadjuvant chemotherapy for unresectable liver metastases. Br J Cancer 97:1035-1039, 2007
39. Bouchahda M, Tanaka K, Adam R, et al: Three-drug chronotherapy via hepatic artery as salvage treatment for patients with liver-only metastases from colorectal cancer. J Clin Oncol 23:275s, 2005 (suppl; abstr 3616)
40. De La Cámara J, Rodriguez J, Rotellar F, et al: Triplet therapy with oxaliplatin, irinotecan, 5-fluorouracil and folinic acid within a combined modality approach in patients with liver metastases from colorectal cancer. J Clin Oncol 22:268s, 2004 (suppl; abstr 3593)
41. Falcone A, Ricci S, Brunetti I, et al: Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as firstline treatment for metastatic colorectal cancer: The Gruppo Oncologico Nord Ouest. J Clin Oncol 25:1670-1676, 2007
42. Fisher GA, Kuo T, Cho CD, et al: A phase II study of gefitinib in combination with FOLFOX-4 (IFOX) in patients with metastatic colorectal cancer. J Clin Oncol 22:248s, 2004 (suppl; abstr 3514)
43. Garassino I, Carnaghi C, Rimassa L, et al: Definitive results of hybrid chemotherapy with intravenous (iv) oxaliplatin (OXA) and folinic acid (FA), and intra-hepatic infusion (HAI) of 5-fluorouracil (5-FU) in patients with colorectal liver metastases. J Clin Oncol 23:288s, 2005 (suppl; abstr 3670)
44. Giacchetti S, Itzhaki M, Gruia G, et al: Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery. Ann Oncol 10:663-669, 1999
45. Gil-Delgado MA, Guinet F, Castaing D, et al: Prospective phase II trial of iriontecan, 5-fluorouracil, and leucovorin in combination as salvage therapy for advanced colorectal cancer. Am J Clin Oncol 24:101-105, 2001
46. Gruenberger T, Schuell B, Kornek G, et al: Neoadjuvant chemotherapy for resectable colorectal cancer liver metastases: Impact on magnitude of liver resection and survival. J Clin Oncol 22:269s, 2004 (suppl; abstr 3598)
47. Ho WM, Mok TS, Ma BB, et al: Liver resection after irinotecan (CPT-11), 5-fluorouracil (5FU) and folinic acid (FA) for patients (pts) with unresectable liver metastases (Mets) from colorectal cancer (CRC). Proc Am Soc Clin Oncol 22:312a, 2003 (abstr 1253)
48. Leonard GD, Fong Y, Jarnagin W, et al: Liver resection after hepatic arterial infusion (HAI) plus systemic oxaliplatin (Oxal) combinations in pretreated patients with extensive unresectable colorectal liver metastases. J Clin Oncol 22:14s, 2004 (suppl; abstr 3542)
49. Martoni A, Pinto C, Di Fabio F, et al: Phase II randomized trial on protracted 5-fluorouracil infusion plus oxaliplatin (FOX) versus capecitabine plus oxaliplatin (XELOX) as first line treatment in advanced colorectal cancer (ACRC): Preliminary results of the Italian FOCA study. J Clin Oncol 23:16s, 2005 (suppl; abstr 3617)
50. Meric F, Patt YZ, Curley SA, et al: Surgery after downstaging of unresectable hepatic tumors with intra-arterial chemotherapy. Ann Surg Oncol 7:490-495, 2000
51. Miyanari N, Mori T, Takahashi K, et al: Evaluation of aggressively treated patients with unresectable multiple liver metastases from colorectal cancer. Dis Colon Rectum 45:1503-1509, 2002
52. Moosmann N, Kern W, Waggershauser T, et al: Hepatic artery infusion of 5-fluorouracil, folinic acid plus oxaliplatin for liver metastasis from colorectal cancer: Final analysis of a phase I-/II-study. J Clin Oncol 23:278s, 2005 (suppl; abstr 3628)
53. Peeters M, Raoul J-L, van Laethem J-L, et al: Cetuximab in combination with irinotecan/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFIRI) in the first-line treatment of metastatic colorectal cancer (mCRC). Eur J Cancer 3:2;188, 2005 (suppl; abstr 664)
54. Rivoire M, De Cian F, Meeus P, et al: Combination of neoadjuvant chemotherapy with cryotherapy and surgical resection for the treatment of unresectable liver metastases from colorectal carcinoma. Cancer 95:2283-2292, 2002
55. Seium Y, Stupp R, Ruhstaller T, et al: Oxaliplatin combined with irinotecan and 5-fluorouracil/ leucovorin (OCFL) in metastatic colorectal cancer: A phase I-II study. Ann Oncol 16:762-766, 2005
56. Seufferlein T, Dittrich C, Riemann J, et al: A phase I/II study of cetuximab in combination with 5-fluorouracil (5-FU)/folinic acid (FA) plus weekly oxaliplatin (L-OHP) (FUFOX) in the first-line treatment of patients with metastatic colorectal cancer (mCRC) expressing epidermal growth factor receptor (EGFR): Preliminary results. J Clin Oncol 23: 281s, 2005 (suppl; abstr 3644)
57. Shankar A, Leonard P, Renaut AJ, et al: Neoadjuvant therapy improves resectability rates for colorectal liver metastases. Ann R Coll Surg Engl 83:85-88, 2001
58. Shimonov M, Hayat H: Alternating hepatic artery chronotherapy with CPT-11 and systemic chronotherapy with 5-FU/FA + carboplatin for metastatic colorectal cancer confined to the liver: A phase II study. J Clin Oncol 23:297s, 2005 (suppl; abstr 3707)
59. Wein A, Riedel C, Kockerling F, et al: Impact of surgery on survival in palliative patients with metastatic colorectal cancer after first line treatment with weekly 24-hour infusion of high-dose 5-fluorouracil and folinic acid. Ann Oncol 12:1721-1727, 2001
60. Ychou M, Viret F, Kramar A, et al: Tritherapy with fluorouracil/ leucovorin, irinotecan and oxaliplatin (FOLFIRINOX): A phase II study in colorectal cancer patients with non-resectable liver metastases. Cancer Chemother Pharmacol 62:195-201, 2008
61. Zelek L, Bugat R, Cherqui D, et al: Multimodal therapy with intravenous biweekly leucovorin, 5-fluorouracil and irinotecan combined with hepatic arterial infusion pirarubicin in non-resectable hepatic metastases from colorectal cancer (a European Association for Research in Oncology trial). Ann Oncol 14:1537-1542, 2003
62. Folprecht G, Grothey A, Alberts S, et al: Neoadjuvant treatment of unresectable colorectal liver metastases: Correlation between tumour response and resection rates. Ann Oncol 16:1311-1319, 2005
63. Elias D, Youssef O, Sideris L, et al: Evolution of missing colorectal liver metastases following inductive chemotherapy and hepatectomy. J Surg Oncol 86:4-9, 2004
64. Schrag D, Weiser M, Schattner M, et al: An increasingly common challenge: Management of the complete responder with multi-focal metastatic colorectal cancer. J Clin Oncol 23:1799-1802, 2005
65. Benoist S, Brouquet A, Penna C, et al: Complete response of colorectal liver metastases after chemotherapy: Does it mean cure? J Clin Oncol 24:3939-3945, 2006
66. Adam R, Pascal G, Castaing D, et al: Tumor progression while on chemotherapy: A contraindication to liver resection for multiple colorectal metastases? Ann Surg 240:1052-1061, 2004
67. Abad A, Antón A, Massuti B, et al: Resectability of liver metastases (LM) in patients with advanced colorectal cancer (ACRC) after treatment with the combination of oxaliplatin (OXA), irinotecan (IRI) and 5FU: Final results of a phase II study. J Clin Oncol 23:275s, 2005 (suppl; abstr 3618)
68. Pozzo C, Basso M, Quirino M, et al: Long-term follow-up of colorectal cancer (CRC) patients treated with neoadjuvant chemotherapy with irinotecan and fluorouracil plus folinic acid (5-FU/FA) for unresectable liver metastases. J Clin Oncol 24:164s, 2006 (suppl; abstr 3576)
69. Greene FL, Page DL, Fleming ID, et al: AJCC Cancer Staging Manual (ed 6). New York, NY, Springer Verlag, 2002
70. Pihl E, Hughes ES, McDermott FT, et al: Lung recurrence after curative surgery for colorectal cancer. Dis Colon Rectum 30:417-419, 1987
71. Poston G, Adam R, Vauthey JN: Downstaging or downsizing: Time for a new staging system in advanced colorectal cancer? J Clin Oncol 24:2702-2706, 2006
72. Chiche L: When is first-line resection of hepatic metastasis indicated? Gastroenterol Clin Biol 27 Spec No 2:B11-B13:B41-B61, 2003